EUVIMEDEUVIMED entdecken
Open Access

Improving nitrofurantoin resistance prediction in Escherichia coli from whole-genome sequence by integrating NfsA/B enzyme assays

Punyawee Dulyayangkul, Jordan E Sealey, Winnie W Y Lee, Naphat Satapoomin, Carlos Reding iD, Kate J Heesom, Philip B Williams, Matthew B Avison iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00242-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Punyawee Dulyayangkul und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Drug Resistance, Bacterial, Escherichia coli, Escherichia coli Proteins, Nitrofurantoin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: UKRI | Medical Research Council (MRC), UKRI | Natural Environment Research Council (NERC), National Institute for Health and Care Research (NIHR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nitrofurantoin resistance in Escherichia coli is primarily caused by mutations damaging two enzymes, NfsA and NfsB. Studies based on small isolate collections with defined nitrofurantoin MICs have found significant random genetic drift in nfsA and nfsB , making it extremely difficult to predict nitrofurantoin resistance from whole-genome sequence (WGS) where both genes are not obviously disrupted by nonsense or frameshift mutations or insertional inactivation. Here, we report a WGS survey of 200 oqxAB -negative E. coli from community urine samples, of which 34 were nitrofurantoin resistant. We characterized individual non-synonymous mutations seen in nfsA and nfsB among this collection using complementation cloning and NfsA/B enzyme assays in cell extracts. We definitively identified R203C, H11Y, W212R, A112E, and A112T in NfsA and R121C, Q142H, F84S, P163H, W46R, K57E, and V191G in NfsB as amino acid substitutions that reduce enzyme activity sufficiently to cause resistance. In contrast, E58D, I117T, K141E, L157F, A172S, G187D, and A188V in NfsA and G66D, M75I, V93A, and A174E in NfsB are functionally silent in this context. We identified that 9/166 (5.4%) nitrofurantoin-susceptible isolates were “pre-resistant,” defined as having loss of function mutations in nfsA or nfsB . Finally, using NfsA/B enzyme assays and proteomics, we demonstrated that 9/34 (26.5%) ribE wild-type nitrofurantoin-resistant isolates also carried functionally wild-type nfsB or nfsB / nfsA . In these cases, NfsA/B activity was reduced through downregulated gene expression. Our biological understanding of nitrofurantoin resistance is greatly improved by this analysis but is still insufficient to allow its reliable prediction from WGS data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, BacterialEscherichia coliEscherichia coli ProteinsNitrofurantoinNitroreductasesHumansAnti-Bacterial AgentsAnti-Infective Agents, UrinaryGenome, BacterialMicrobial Sensitivity TestsMutationWhole Genome Sequencing

Stichwörter der Autor:innen

community-acquired infectionsdiagnosticsgenome analysisurinary tract infection

Substanzen

Anti-Bacterial AgentsAnti-Infective Agents, UrinaryEscherichia coli ProteinsNfsA protein, E coliNfsB protein, E coliNitrofurantoinNitroreductases

Autor:innen und Institutionen

  • School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand.
  • University of Bristol Proteomics Facility, Bristol, United Kingdom.
  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.

ORCID-Profile: Carlos Reding, Matthew B Avison

Förderung

  • UKRI | Medical Research Council (MRC)
  • UKRI | Natural Environment Research Council (NERC)
  • National Institute for Health and Care Research (NIHR)
  • Llywodraeth Cymru (Welsh Government)
  • UKRI | MRC | Medical Research Foundation

Zitieren

APA

Dulyayangkul, P., Sealey, J. E., Lee, W. W. Y., Satapoomin, N., Reding, C., Heesom, K. J., Williams, P. B., & Avison, M. B. (2024). Improving nitrofurantoin resistance prediction in Escherichia coli from whole-genome sequence by integrating NfsA/B enzyme assays. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00242-24

Vancouver

Dulyayangkul P, Sealey JE, Lee WWY, Satapoomin N, Reding C, Heesom KJ, et al. Improving nitrofurantoin resistance prediction in Escherichia coli from whole-genome sequence by integrating NfsA/B enzyme assays. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00242-24

BibTeX
@article{Dulyayangkul2024,
  author = {Dulyayangkul, Punyawee and Sealey, Jordan E and Lee, Winnie W Y and Satapoomin, Naphat and Reding, Carlos and Heesom, Kate J and Williams, Philip B and Avison, Matthew B},
  title = {Improving nitrofurantoin resistance prediction in Escherichia coli from whole-genome sequence by integrating NfsA/B enzyme assays},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00242-24}
}
Kostenlos starten →